More on Arena Pharmaceuticals (ARNA): Q2 EPS comes up short but beats top line estimates. Total...

More on Arena Pharmaceuticals (ARNA): Q2 EPS comes up short but beats top line estimates. Total revenue jumped over 500% Y/Y, however the increase was primarily the result of the $20M milestone payment earned under its marketing and supply agreement with Japanese drug maker Eisai. Bottom line results were hit by higher losses from the revaluation of derivative liabilities. Shares -3.6% AH.

From other sites
Comments (7)
  • topperg
    , contributor
    Comments (200) | Send Message
    seems very good,,,cc will be the winning #
    9 Aug 2012, 04:27 PM Reply Like
  • Foreverlong07
    , contributor
    Comments (77) | Send Message
    Shares should rebound quickly from the AH decline, because this doesn't change the great potential for Belviq or Arena IMO.


    Still, stay long and strong.
    9 Aug 2012, 04:28 PM Reply Like
  • montanamark
    , contributor
    Comments (1452) | Send Message
    $20 mil is still $20mil
    9 Aug 2012, 04:31 PM Reply Like
  • montanamark
    , contributor
    Comments (1452) | Send Message
    green already. sheesh - fast dip
    9 Aug 2012, 04:40 PM Reply Like
  • jacktrout24
    , contributor
    Comment (1) | Send Message
    Type II Diabetes is a world wide epidemic, health officials say that patients that can lose the first 10 to 15 lbs is the most important and crucial factor in curving this disease in the right direction, with of course exercise, diet and medical supervision. This is will be the difference this time around with weight lose drugs like Belviq and world wide sales and distribution. I'm no fan of the old commercials of sitting on a couch and "take this pill to lose weight!"


    That thought makes me laugh and puke. This makes a lot more sense that Belviq will be manufactured and will be prescribed by doctors for a program of health benefit.


    There is a need for folks who suffer from Type II Diabetes or are at risk to become, this new drug could help folks who respond to it's benefits.
    9 Aug 2012, 06:00 PM Reply Like
  • New Superhuman
    , contributor
    Comments (1180) | Send Message
    I can't believe we are getting a second chance to get into what may be the best performing stock of the year. This is your chance folks.


    ARNA doubles going into the end of the year. This is an early retirement stock. Get in now or miss out again.
    9 Aug 2012, 11:23 PM Reply Like
  • chuckwagon10
    , contributor
    Comments (9) | Send Message
    Was anyone expecting the earnings to be anything ground breaking.
    Other than the 20M, no impact from approval. The real story will be revealed in 2013. Long ARNA and riding it out and reloading on dips like this.
    10 Aug 2012, 10:54 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs